Literature DB >> 29804927

Low-pleasure beliefs in patients with schizophrenia and individuals with social anhedonia.

Yin Yang1, Zhuo-Ya Yang2, Ying-Min Zou2, Hai-Song Shi3, Yi Wang1, Dong-Jie Xie2, Rui-Ting Zhang2, Simon S Y Lui4, Alex C Cohen5, Gregory P Strauss6, Eric F C Cheung7, Raymond C K Chan8.   

Abstract

Anhedonia in schizophrenia has been suggested to comprise a set of low-pleasure beliefs, defined as beliefs that certain things/activities were not pleasurable or that one does not feel pleasant generally. However, no instrument has been intentionally developed to specifically measure low-pleasure beliefs, and there is a paucity of empirical evidence for low-pleasure beliefs and their relationship with anhedonia in both patients with schizophrenia and individuals with high social anhedonia. We developed and validated the Beliefs About Pleasure Scale (BAPS) using non-clinical (Studies 1, 2 & 3), chronic schizophrenia (Study 2), and first episode schizophrenia (Study 3) samples. Across these studies, we examined psychometric properties of the BAPS, including temporal stability, internal consistency, factor structure, and convergent validity. The 22 BAPS items loaded onto 4 factors, namely the "Devaluation of Pleasure", the "Pleasurable Activity Expectancies", the "Negative Outcomes Expectancies", and the "Attention to Pleasure". The measure demonstrated good internal consistency and convergent validity in each sample. Moreover, both individual with schizophrenia and non-clinical participants with high social anhedonia scored higher on the BAPS than controls (Study 3), supporting construct validity. These findings provide preliminary evidence for the presence of low-pleasure beliefs in both clinical and subclinical groups and suggest that the BAPS has promising initial psychometric properties. The BAPS will be useful for exploring the cognitive component of anhedonia and provides a novel assessment for mechanism of change in psychosocial treatment studies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anhedonia; Beliefs about pleasure scale; Experience of pleasure; Low-pleasure beliefs; Schizophrenia

Mesh:

Year:  2018        PMID: 29804927     DOI: 10.1016/j.schres.2018.05.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Expanding the positivity offset theory of anhedonia to the psychosis continuum.

Authors:  Marcel Riehle; Matthias Pillny; Tania M Lincoln
Journal:  Schizophrenia (Heidelb)       Date:  2022-05-03

2.  Emotional response in schizophrenia to the "36 questions that lead to love": Predicted and experienced emotions regarding a live social interaction.

Authors:  Elizabeth A Martin; Mayan K Castro; Lilian Y Li; Emily J Urban; Melody M Moore
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

3.  Electrophysiological responses to images ranging in motivational salience: Attentional abnormalities associated with schizophrenia-spectrum disorder risk.

Authors:  Elizabeth A Martin; Lilian Yanqing Li; Mayan K Castro
Journal:  Sci Rep       Date:  2020-03-12       Impact factor: 4.379

4.  A Bioecosystem Theory of Negative Symptoms in Schizophrenia.

Authors:  Gregory P Strauss
Journal:  Front Psychiatry       Date:  2021-03-25       Impact factor: 4.157

5.  Sexual Dysfunction in Chronically Medicated Male Inpatients With Schizophrenia: Prevalence, Risk Factors, Clinical Manifestations, and Response to Sexual Arousal.

Authors:  Dianying Liu; Shaohua Liu; Meihong Xiu; Hongdong Deng; Huiyun Guo; Wanglin Liu; Delong Zhang; Zhongzhen Mao; Dan Huang; Donghua Huang; Qiumei Miao; Lijuan Qiu; Ning Olivia Zhao; Hanjing Emily Wu; Xiangyang Zhang
Journal:  Front Psychiatry       Date:  2022-01-14       Impact factor: 4.157

6.  How did that interaction make you feel? The relationship between quality of everyday social experiences and emotion in people with and without schizophrenia.

Authors:  Jasmine Mote; David E Gard; Rachel Gonzalez; Daniel Fulford
Journal:  PLoS One       Date:  2019-09-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.